Aphria (TSE:APHA) had its price target decreased by Cormark from C$14.00 to C$8.00 in a research report sent to investors on Wednesday morning, BayStreet.CA reports.
A number of other research analysts have also recently issued reports on APHA. CIBC decreased their price objective on shares of Aphria from C$7.00 to C$6.50 in a research note on Wednesday. Jefferies Financial Group decreased their price objective on shares of Aphria from C$15.00 to C$11.00 in a research note on Friday, October 11th. Eight Capital decreased their price objective on shares of Aphria from C$11.00 to C$9.00 in a research note on Wednesday. Finally, Canaccord Genuity decreased their price objective on shares of Aphria from C$18.00 to C$16.00 in a research note on Wednesday, June 19th.
Shares of APHA opened at C$6.24 on Wednesday. Aphria has a 12 month low of C$4.76 and a 12 month high of C$20.06. The firm’s 50 day moving average is C$8.07 and its 200-day moving average is C$9.99. The stock has a market capitalization of $1.60 billion and a PE ratio of -89.14. The company has a current ratio of 5.64, a quick ratio of 4.38 and a debt-to-equity ratio of 28.19.
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Recommended Story: P/E Growth (PEG)
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.